Amneal patent expiration
1. Lyvispah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654124 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(15 years from now) | |
| US11931328 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(15 years from now) | |
| US10792262 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(15 years from now) | |
| US11491125 | AMNEAL | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
Sep, 2041
(17 years from now) | |
| US11850225 | AMNEAL | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
Sep, 2041
(17 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Method for treating spasticity; Treatment of spasticity resulting from spinal cord injuries and other spinal cord diseases
Dosage: GRANULES
More Information on Dosage
LYVISPAH family patents
2. Ongentys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8907099 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
May, 2027
(2 years from now) | |
| US8168793 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
Apr, 2029
(4 years from now) | |
| US9630955 | AMNEAL | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9550759 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
Jul, 2026
(1 year, 11 months from now) | |
| US9745290 | AMNEAL | Dosage regimen for COMT inhibitors |
Oct, 2027
(3 years from now) | |
| US8524746 | AMNEAL | Dosage regimen for COMT inhibitors |
Jul, 2029
(4 years from now) | |
| US10071085 | AMNEAL | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) | |
| US10583130 | AMNEAL | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) | |
| US10357468 | AMNEAL | Medicaments for slowing Parkinson's disease |
May, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson’s disease experiencing off episodes by reducing o-methylation of l-dopa; Adjunctive treatment to levodopa/carbidopa in patients wi...
Dosage: CAPSULE
More Information on Dosage
ONGENTYS family patents
3. Tigecycline patent
expiration
Can you believe TIGECYCLINE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855335 | AMNEAL | Tigecycline composition for injection |
Apr, 2033
(8 years from now) | |
| US9855355 | AMNEAL | Method and device for plasma-treating hollow bodies |
Apr, 2033
(8 years from now) | |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 02 August, 2018
Treatment: NA
Dosage: POWDER
More Information on Dosage
TIGECYCLINE family patents
4. Zomig patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5466699 | AMNEAL | Indolyl compounds for treating migraine |
Nov, 2012
(11 years ago) | |
|
US5466699 (Pediatric) | AMNEAL | Indolyl compounds for treating migraine |
May, 2013
(11 years ago) | |
| US7220767 | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
Nov, 2020
(3 years ago) | |
| US6750237 | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
Nov, 2020
(3 years ago) | |
|
US6750237 (Pediatric) | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
May, 2021
(3 years ago) | |
|
US7220767 (Pediatric) | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
May, 2021
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 12, 2018 |
Drugs and Companies using ZOLMITRIPTAN ingredient
Market Authorisation Date: 16 September, 2013
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: SPRAY
How can I launch a generic of ZOMIG before it's drug patent expiration?
More Information on Dosage
ZOMIG family patents